SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
Barclays Reaffirms Their Buy Rating on Springworks Therapeutics (SWTX)
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Springworks Therapeutics (SWTX)
Barclays Issues a Buy Rating on Springworks Therapeutics (SWTX)
Sector Update: Health Care Stocks Mixed Premarket Monday
Sector Update: Health Care
Express News | SpringWorks Therapeutics Inc - in H2 2024, Plans to File Marketing Authorization Application With EMA for Mirdametinib
Express News | SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults With Nf1-Pn
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
Express News | SpringWorks Therapeutics Inc : JP Morgan Cuts Target Price to $64 From $77
GSK, SpringWorks End Collaboration Agreement
Express News | SpringWorks Therapeutics Inc Says Termination Of License Deal Does Not Trigger Any Payment Obligations On Part Of Co/any Other Material Wind-Down Costs
Express News | SpringWorks Therapeutics Says Termination Does Not Affect Co's Rights To Continue Developing Or Commercializing Its Products Or Product Candidates; Expects That GSK Will Continue Ongoing Clinical Trials Under License Agreement
Express News | SpringWorks Therapeutics Inc - Termination of License Deal Does Not Trigger Any Payment Obligations on Part of Co/Any Other Material Wind-Down Costs
Express News | SpringWorks Therapeutics Inc - Co Expects That GSK Will Continue Ongoing Clinical Trials Under License Agreement
Express News | SpringWorks Therapeutics Inc - Termination Does Not Affect Co's Rights to Continue Developing or Commercializing Its Products or Product Candidates
Express News | SpringWorks Therapeutics:Deal Termination Between Co & Glaxosmithkline Intellectual Property Development Effective 180 Days After Notice Receipt
Express News | SpringWorks Therapeutics:Got Notice of Termination of Amended & Restated Collaboration and License Agreement, Dated Sept 6, 2022, Between Co & GSK
Insider Sale: Director Julie Hambleton Sells Shares of SpringWorks Therapeutics Inc (SWTX)
No Data